MedTrace Logo

A Pilot Study of TRV130 for the Treatment of Fracture Pain

NCT02520297 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2020-09-07

Study results available
· View outcomes & findings →

Summary

The primary objective is to evaluate the analgesic efficacy of TRV130 for moderate to severe acute pain in patients presenting to the emergency department (ED) with a suspected/known, unilateral, closed long bone fracture.

Conditions

Interventions

DRUG

TRV130

Drug

Sponsors & Collaborators

  • Kestrel Biologic

    collaborator INDUSTRY

  • Trevena Inc.

    lead INDUSTRY

Principal Investigators

  • Indiana University · Indiana University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-20
Primary Completion
2015-10-23
Completion
2015-10-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02520297 on ClinicalTrials.gov